Rofecoxib Pellets

(Product under development)
Rofecoxib PelletsRofecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that has now been withdrawn over safety concerns. Rofecoxib was approved by the Food and Drug Administration (FDA) on May 20, 1999, and was marketed under the brand names Vioxx, Ceoxx, and Ceeoxx.

Rofecoxib gained widespread acceptance among physicians treating patients with arthritis and other conditions causing chronic or acute pain. Worldwide, over 80 million people were prescribed rofecoxib at some time.

On September 30, 2004, Merck voluntarily withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use.

Rofecoxib was one of the most widely used drugs ever to be withdrawn from the market. In the year before withdrawal, Merck had sales revenue of US$2.5 billion from Vioxx.

Rofecoxib was available on prescription as tablets and as an oral suspension. It was available by injection for hospital use.

Available Form:
Rofecoxib Pellets
Rofecoxib Granules

Umang Pharmatech equipments used for production of Rofecoxib Pellets:
Drug Layering, Fluid Bed Dryer, Fluid Bed Coater, Sifter & Blender, Extruder and Twin spheronizer.


Rofecoxib Pellets
Systematic (IUPAC) Name
Rofecoxib Pellets
Identifiers
Rofecoxib Pellets
Chemical data
4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one
CAS number : 162011-90-7
ATC code : M01AH02
PubChem : CID 5090
DrugBank : APRD00151
ChemSpider : 4911
UNII : 0QTW8Z7MCR
KEGG : D00568
ChEBI : CHEBI:8887
ChEMBL : CHEMBL122
Formula : C17H14O4S
Mol. mass : 314.357 g/mol


* All transactions are carried out in conformity with patent laws applicable in the user country. Active pharmaceutical ingredients or formulations thereof will not be supplied in countries where the same is under patent protection except as and if permitted under law of the country for research and development purposes only.
Extruder Spheronizer Email Us Umang Pharmatech
TESTIMONIAL